Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$8.9MBeat by $837.5K
EPS-$1.22Miss by $0.16
Revenue estimate$8.0M
EPS estimate-$1.06

Next report

Nov 9, 2026 (In 1 week)
Revenue estimate$7.6M
EPS estimate-$1.18

Financials

Q2 2026

Income statement

See full
Revenue$8.9M—
Operating income-$122.3M-37.7%
Net income-$112.5M-45.1%
EPS (diluted)-$1.22-38.6%

Balance sheet

See full
Cash & equivalents$272.6M+138%
Total debt$29.3M+10.2%
Total equity$1.2B+24.9%
Total assets$1.3B+25.8%

Cash flow

See full
Operating cash flow-$88.2M-41.2%
CapEx$866.0K+30.6%
Free cash flow-$89.1M-41.1%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$3.17B+14.6%
Enterprise value$2.93B+17.3%
P/S13.6×—

Profitability

See full
Operating margin-92.7%—
Net margin-74.8%—
FCF margin-48.6%—

Returns & leverage

See full
Return on equity-16.2%-5.7pp
Debt / equity0×0.0×
Current ratio10.5×-1.9×

FAQ

When did IDEAYA Biosciences, Inc. report Q2 2026 earnings?
IDEAYA Biosciences, Inc. (IDYA) reported Q2 2026 earnings on August 4, 2026 before market open.
What were IDEAYA Biosciences, Inc.'s Q2 2026 revenue and EPS?
IDEAYA Biosciences, Inc. reported revenue of $8.9M and eps of $-1.22 for Q2 2026.
Did IDEAYA Biosciences, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $8.0M by $837.5K. EPS missed the consensus estimate of $-1.06 by $0.16.
How did IDEAYA Biosciences, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 38.6% from $-0.88.
Where can I find IDEAYA Biosciences, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-331381) and the 10-Q periodic report (0001193125-26-332774) directly on SEC EDGAR. The filing index links above go to sec.gov.